3Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline: Recommendation S for venous thromboembolism prophylaxis and treatment in patients with cancer[J]. J Clin Oncol,2007,25:5490 - 5505.
4Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology Guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol, 2007, 25:5490-5505.
5Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia, 2002, 4:465-473.
6Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med, 2007, 13:362-367.
7Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA, 2005, 293 : 715-722.
8Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition ). Chest, 2008, 133 (6 suppl) :381S-453S.
9Kuter DJ. Thrombotic complications of central venous catheters in cancer patients. The Oncologist, 2004, 9:207-216.
10Monreala M, Trujillo-Santos J. Screening for occult cancer in patients with acute venous thromboembolism. Curr Opin Pulm Med, 2007, 13:368-371.
